Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • 2014 Report on Tuberculosis Research Funding Trends, 2005–2013

    Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

    5 hours ago | TAG
  • IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes

    While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.

    16 October 2014 | HIVandHepatitis.com
  • Unique 'pay if you clear' proposal for new hepatitis drug

    The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

    15 October 2014 | BBC
  • Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

    The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

    15 October 2014 | Fair Pricing Coalition
  • As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

    As Gilead Sciences launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions.

    10 October 2014 | Forbes
  • Sovaldi ‘unaffordable’ says NHS documents

    Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after new data shows it would cost the health service £1 billion a year to fund.

    08 October 2014 | Pharmafile
  • How Some State Medicaid Programs Limit Drugs to Only the Sickest Patients

    Because of its high cost, some state Medicaid programs and prison systems are refusing to provide Sovaldi to any but the sickest patients. Most recently, Oregon last month threatened to limit access to the drug unless it can get Sovaldi at a deeply discounted price. What can states do to hold down drug costs? Drug pricing is a complicated and opaque process. Here are some of the basics.

    07 October 2014 | Governing.com
  • Treatment Action Campaign faces closure

    After almost two decades spent fighting for HIV treatment and access to medicines, the Treatment Action Campaign (TAC) may close its doors due to a severe funding shortage.

    01 October 2014 | Health-e
  • France uses tax to put pressure on hepatitis C drug prices

    France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.

    01 October 2014 | Reuters
  • Hard choices in Russia as the final HIV grant proposal is submitted

    The concept note delivered on 8 September for Russia's last HIV grant from the Global Fund was a perfect illustration of the conundrum facing a growing number of Eastern European/Central Asian countries: how to do more with less to fight a widening HIV epidemic. As more countries from the region 'graduate' from Global Fund eligibility due to their income classification, the funds that they could once count on to support prevention, harm reduction and other programs targeting vulnerable populations are disappearing. And there is little evidence that most national budgets are prepared or able to fill the vacuum.

    25 September 2014 | Aidspan
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.